Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •One of the following diagnoses:
• •* Acute myeloid leukemia
• •* Accelerated/blastic phase of a myeloproliferative disorder (i.e., greater than 10% blasts in bone marrow or presence of extramedullary disease)
• •* Myelodysplastic syndrome
• •* Acute lymphocytic leukemia with expression of CD33
• •* Greater than 20% blast population
• •* No evidence of CNS disease
• •Relapsed after previously achieving complete remission
• •Must have previously had peripheral blood stem cells or bone marrow cells harvested and cryopreserved while in remission
• •Greater than 25% of bone marrow blasts must be CD33 positive
• •PATIENT CHARACTERISTICS:
• •Age:
• •18 and over
• •Performance status:
• •Not specified
• •Life expectancy:
• •Not specified
• •Hematopoietic:
• •Not specified
• •Hepatic:
• •Not specified
• •Renal:
• •Creatinine no greater than 1.5 mg/dL OR
• •Creatinine clearance at least 60 mL/min
• •Cardiovascular:
• •LVEF greater than 50% by ECG or MUGA
• •No history of cardiomyopathy or symptomatic congestive heart failure
• •Pulmonary:
• •DLCO at least 50% predicted
• •Other:
• •Not pregnant or nursing
• •Negative pregnancy test
• •HIV negative
• •No other concurrent active malignancy
• •No known sensitivity to E. coli derived products
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •See Disease Characteristics
• •Chemotherapy
• •See Disease Characteristics
• •Endocrine therapy
• •Not specified
• •Radiotherapy
• •Not specified
• •Surgery
• •Not specified